Abstract
The cholinergic system impairment observed in Alzheimers disease (AD) patients leads to the cognitive, global and behavioral dysfunction commonly associated with dementia. The only treatment for AD has been the use of inhibitors of acetylcholinesterase (AChE) (E.C. 3.1.1.7), which is one of the several proteins associated with amyloid plaque deposits. Recently, novel dual inhibitors of AChE have been developed that target both the active site of the enzyme as well as the peripheral anionic site (PAS). Such inhibitors prevent the aggregation of amyloid-β-peptide (Aβ) into Alzheimers fibrils. The incorporation of AChE, as a "chaperone" into amyloid aggregates results in the modification of the biochemical properties of the enzyme, including: sensitivity to low pH, inhibition at high substrate concentration, and increases of the Aβ neurotoxocity. Congo Red dye stabilizes the Aβ monomer, is able to inhibit oligomerization, and inhibits the binding of AChE to Aβ. However no effect of Congo Red on the binding of AChE to the Ab preformed fibrils was observed. These studies suggest that different interactions between Aβ soluble-AChE and Aβ fibrils-AChE take place during the association between them. Docking studies were performed to evaluate the binding of Congo Red to Aβ in order to identify putative binding sites in the Ab monomer that might interact with AChE. The binding site involves a region between residues 12 and 16. Finally, recent studies are consistent with the idea that a attenuating β-catenin loss of function of Wnt signaling components may play a role in the progression of neurodegenerative disease, such as AD, providing a connection between AChE-Aβ neurotoxicity and the Wnt signal transduction pathway.
Keywords: acetylcholinesterase, alzheimers disease, amyloid peptide, congo red, peripheral anionic site
Current Alzheimer Research
Title: Acetylcholinesterase-Amyloid-β-peptide Interaction: Effect of Congo Red and the Role of the Wnt Pathway
Volume: 2 Issue: 3
Author(s): Nibaldo C. Inestrosa, Alejandra Alvarez, Margarita C. Dinamarca, Tomas Perez-Acle and Marcela Colombres
Affiliation:
Keywords: acetylcholinesterase, alzheimers disease, amyloid peptide, congo red, peripheral anionic site
Abstract: The cholinergic system impairment observed in Alzheimers disease (AD) patients leads to the cognitive, global and behavioral dysfunction commonly associated with dementia. The only treatment for AD has been the use of inhibitors of acetylcholinesterase (AChE) (E.C. 3.1.1.7), which is one of the several proteins associated with amyloid plaque deposits. Recently, novel dual inhibitors of AChE have been developed that target both the active site of the enzyme as well as the peripheral anionic site (PAS). Such inhibitors prevent the aggregation of amyloid-β-peptide (Aβ) into Alzheimers fibrils. The incorporation of AChE, as a "chaperone" into amyloid aggregates results in the modification of the biochemical properties of the enzyme, including: sensitivity to low pH, inhibition at high substrate concentration, and increases of the Aβ neurotoxocity. Congo Red dye stabilizes the Aβ monomer, is able to inhibit oligomerization, and inhibits the binding of AChE to Aβ. However no effect of Congo Red on the binding of AChE to the Ab preformed fibrils was observed. These studies suggest that different interactions between Aβ soluble-AChE and Aβ fibrils-AChE take place during the association between them. Docking studies were performed to evaluate the binding of Congo Red to Aβ in order to identify putative binding sites in the Ab monomer that might interact with AChE. The binding site involves a region between residues 12 and 16. Finally, recent studies are consistent with the idea that a attenuating β-catenin loss of function of Wnt signaling components may play a role in the progression of neurodegenerative disease, such as AD, providing a connection between AChE-Aβ neurotoxicity and the Wnt signal transduction pathway.
Export Options
About this article
Cite this article as:
Inestrosa C. Nibaldo, Alvarez Alejandra, Dinamarca C. Margarita, Perez-Acle Tomas and Colombres Marcela, Acetylcholinesterase-Amyloid-β-peptide Interaction: Effect of Congo Red and the Role of the Wnt Pathway, Current Alzheimer Research 2005; 2 (3) . https://dx.doi.org/10.2174/1567205054367928
DOI https://dx.doi.org/10.2174/1567205054367928 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Estimating Alzheimer’s Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia
Current Alzheimer Research Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology Neurotoxicity of Engineered Nanoparticles from Metals
CNS & Neurological Disorders - Drug Targets Biochemical and Histochemical Comparison of Cholinesterases in Normal and Alzheimer Brain Tissues
Current Alzheimer Research Acceptability and Results of Dementia Screening Among Older Adults in the United States
Current Alzheimer Research Subclinical Hypothyroidism and Cognitive Dysfunction in the Elderly
Endocrine, Metabolic & Immune Disorders - Drug Targets A Mini-Review on the Effectiveness of Peptoids as Therapeutic Interventions against Neurodegenerative Diseases
Current Protein & Peptide Science Neuroprotective Activities of Marine Natural Products from Marine Sponges
Current Medicinal Chemistry Behcets Syndrome: Literature Review
Current Rheumatology Reviews Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research Are Raw Scores on Memory Tests Better than Age- and Education- Adjusted Scores for Predicting Progression from Amnesic Mild Cognitive Impairment to Alzheimer Disease ?
Current Alzheimer Research Combining Multimodal Neuroimaging Biomarkers in the Diagnosis of Alzheimer’s Disease and Mild Cognitive Impairment
Neuroscience and Biomedical Engineering (Discontinued) Patent Selections
Recent Patents on Drug Delivery & Formulation Accuracy of Ultrasound Imaging Technique for Assessing Lipoatrophy in HIV-Infected Subjects
Current HIV Research Natural Products Combating Neurodegeneration: Parkinson’s Disease
Current Drug Metabolism Preventive Antidepressant use in Patients with Hepatitis C Treated with Interferon-Alfa: a Systematic Review
Current Psychiatry Reviews The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research